[Viva] Fwd: TreatmentUpdate 199 - Integrase inhibitors

[Tami Starlight]

FYI


Hiy Hiy/Thank you/Merci
*Tami M. Starlight*
Unceded & occupied Coast Salish Territory
Vancouver, Canada
tamistarlight at gmail.com
https://www.facebook.com/tami.m.starlight
http://theantioppressionnetwork.wordpress.com/
https://www.facebook.com/pages/Decolonize-Anti-Oppression-Workshop-Tour-with-Tami-Starlight/327348970683291


     TreatmentUpdate 199 - Integrase inhibitors
     [image: TreatmentUpdate Banner]        *TreatmentUpdate*
199<http://www.catie.ca/en/treatmentupdate/treatmentupdate-199?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=121613>
December 2013

*Know your integrase
inhibitors*<http://www.catie.ca/en/treatmentupdate/treatmentupdate-199/anti-hiv-agents/know-your-integrase-inhibitors?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=121613>

Anti-HIV drugs can be divided into several classes, such as nukes,
non-nukes, protease inhibitors, co-receptor blockers and so on. The latest
class of medicines for the treatment of HIV is called integrase inhibitors.

*Dolutegravir approved in Canada—what you need to
know*<http://www.catie.ca/en/treatmentupdate/treatmentupdate-199/anti-hiv-agents/dolutegravir-approved-canada-what-you-need-know?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=121613>

Dolutegravir is the latest integrase inhibitor to be approved in Canada.
Read more about drug interactions, side effects and other important
information.

*Dolutegravir vs. darunavir for the initial treatment of
HIV*<http://www.catie.ca/en/treatmentupdate/treatmentupdate-199/anti-hiv-agents/dolutegravir-vs-darunavir-initial-treatment-hiv?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=121613>

Darunavir is a potent anti-HIV drug and an important part of treatment
regimens for many HIV-positive people. Researchers in the U.S and Europe
conducted a study called Flamingo that compared a darunavir-based regimen
to dolutegravir-based combination therapy in the initial treatment of HIV
infection. Dolutegravir-based regimens were found to be statistically
superior.

*Dolutegravir vs. raltegravir—results after two
years*<http://www.catie.ca/en/treatmentupdate/treatmentupdate-199/anti-hiv-agents/dolutegravir-vs-raltegravir-results-after-two-ye?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=121613>

In a study called Spring-2, researchers in Canada, Australia, Europe and
the U.S. recruited just over 800 HIV-positive volunteers to compare the
effectiveness of a dolutegravir-based regimen to one based on the integrase
inhibitor raltegravir (Isentress). Researchers found that after two years
both integrase inhibitors were generally safe, well tolerated and effective.

*Resistance to integrase
inhibitors*<http://www.catie.ca/en/treatmentupdate/treatmentupdate-199/anti-hiv-agents/resistance-integrase-inhibitors?utm_source=tu&utm_medium=email&utm_content=en&utm_campaign=121613>

HIV has the ability to mutate (or change) and develop the capacity to
resist the effects of treatment. The chance of such changes greatly
increases when doses of treatment are missed or skipped. Researchers in
North Carolina have been studying HIV’s ability to resist treatment,
particularly integrase inhibitors.
         [image: Twitter] <http://twitter.com/#!/CATIEInfo>     [image:
Facebook] <http://www.facebook.com/pages/CATIEInfo/104321259649840>     [image:
youtube] <http://www.youtube.com/catieinfo>
    <http://www.catie.ca>

CATIE is Canada's source for up-to-date, unbiased information about HIV and
hepatitis C

*Tel: 1-800-263-1638 <1-800-263-1638>*

*www.catie.ca <http://www.catie.ca> • www.hepCinfo.ca
<http://www.hepcinfo.ca>*

Permission to reproduce <http://www.catie.ca/en/permission-reproduce>
CATIE Privacy Statement <http://www.catie.ca/en/catie-privacy-statement>
Disclaimer

Decisions about particular medical treatments should always be made in
consultation with a qualified medical practitioner knowledgeable about
HIV-related illness and the treatments in question.
More...<http://www.catie.ca/en/disclaimer>
Third-Party Website Disclaimer

This e-Bulletin contains links to third party Websites ("Linked Sites").
The Linked Sites are not under the control of CATIE and CATIE is not
responsible for the contents of any Linked Site, including any link
contained in a Linked Site or any changes or updates to a Linked Site. The
Linked Sites may not be available in French or English. CATIE is providing
these links to you only as a convenience, and the inclusion of any link
does not imply endorsement by CATIE of the Linked Site or any association
with its operators. We do not guarantee the accuracy or completeness of any
information accessed through or published or provided by the Linked Site
and if you rely upon any such information, you do so entirely at your own
risk. You are responsible for viewing and abiding by the privacy statements
and terms of use posted at the Linked Sites. Any specific comments or
inquiries regarding the Linked Sites should be directed to the operator of
the Linked Site.




--
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20131216/4121beba/attachment.html>